Skip to main content
. 2017 Sep 8;8(54):92090–92105. doi: 10.18632/oncotarget.20760

Figure 1. Characterization of EGFR expression in head and neck squamous cell carcinoma (HNSCC) cells, treatment effect of cetuximab and in vitro cell binding assay of radiolabeled cetuximab.

Figure 1

(a) Expression level of EGFR protein in HNSCC cells by western blot. (b) Flow cytometry in HNSCC cells with cetuximab antibody. Gray shaded curve, isotype control; black lined curve, cetuximab. (c) The cytotoxic effect of cetuximab in SNU-1066 HNSCC cells exposed to different concentrations of cetuximab. The viability of SNU1066 cells was evaluated by the MTS assay. (d) In vitro cell binding assay of 64Cu-PCTA-cetuximab (64Cu-CET) and 177Lu-PCTA-cetuximab (177Lu-CET) in HNSCC cells. (e) In vitro therapeutic efficacy of 177Lu-PCTA-cetuximab in SNU-1066 cells. The survival rate (%) of SNU1066 cells was evaluated by Accustain solution (DigitalBio). CON; control, CET; cetuximab. *, vs. control, P < 0.05 (f) Therapeutic efficacy of cetuximab in SNU-1066 HNSCC xenograft model. The relative tumor volumes were measured after injection of saline (control) and six doses of cetuximab (10 mg/kg, thrice per week for 2 weeks). *, vs. control, P <0.05; a.u., arbitrary unit.